| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 7 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 15 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 18 | | |
| | | | | 19 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 45 | | | |
| | | | | A-1 | | |
Proposal
|
| |
Voting Choices and Board Recommendation
|
|
Proposal 1: Election of Directors
|
| |
•
vote in favor of all nominees;
|
|
|
•
withhold authority to vote for all nominees; or
|
| ||
|
•
withhold authority to vote for any specified nominee.
|
| ||
| The Board recommends a vote FOR each of the nominees. | | ||
Proposal 2: Approval of an amendment and restatement of our 2014 Equity Incentives Plan.
|
| |
•
vote in favor of proposal;
|
|
|
•
vote against proposal; or
|
| ||
|
•
abstain from voting on proposal.
|
| ||
| The Board recommends a vote FOR approval. | | ||
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm
|
| |
•
vote in favor of ratification;
|
|
|
•
vote against ratification; or
|
| ||
|
•
abstain from voting on ratification.
|
| ||
| The Board recommends a vote FOR ratification. | | ||
Proposal 4: Advisory Proposal to Approve Executive Compensation
|
| |
•
vote in favor of proposal;
|
|
|
•
vote against proposal; or
|
| ||
|
•
abstain from voting on proposal.
|
| ||
| The Board recommends a vote FOR the advisory vote to approve executive compensation. | |
Proposal
|
| |
Required Vote
|
| |
Abstentions and Broker Non-Votes
|
|
Proposal 1: Election of Directors | | | Subject to our Majority Voting Policy described below, the affirmative vote of a plurality of shares of Common Stock cast by stockholders present at the Annual Meeting, in person or by proxy, is required to elect each of the nominees. | | | Broker non-votes are not counted and have no effect on the results of the vote. | |
Proposal 2: Approval of an amendment and restatement of our 2014 Equity Incentives Plan. | | | A majority of the votes properly cast in favor of the proposal, by stockholders present at the Annual Meeting, in person or by proxy, is required to approve the proposal. | | | Abstentions and broker non-votes are not counted and have no effect on the results of the vote. | |
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm | | | A majority of the votes properly cast in favor of the proposal, by stockholders present at the Annual Meeting, in person or by proxy, is required to approve the proposal. | | | Abstentions are not counted and have no effect on the results of the vote. | |
Proposal 4: Advisory Proposal to Approve Executive Compensation | | | A majority of the votes properly cast in favor of the proposal, by stockholders present at the Annual Meeting, in person or by proxy, is required to approve the proposal. | | | Abstentions and broker non-votes are not counted and have no effect on the results of the vote. | |
| | |
Timothy C.
Barabe (1) |
| |
Susan L.
Kelley (3) |
| |
Ronald M.
Lindsay (3) |
| |
Michael D.
Loberg (2)(3) |
| |
William G.
Messenger (1)(2) |
| |
Ran
Nussbaum |
| |
Paolo
Pucci |
| |
Patrick J.
Zenner (1)(2) |
| ||||||||||||||||||||||||
High level of financial literacy
|
| | | | X | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Relevant biotechnology business experience
|
| | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Extensive knowledge of drug research and development
|
| | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | |
Extensive knowledge of drug commercialization and marketing
|
| | | | | | | | | | | | | | | | X | | | | | | X | | | | | | | | | | | | | | | | | | X | | | | | | X | | |
Expertise in corporate governance and
business ethics |
| | | | X | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Diversity of background, professional experience or culture
|
| | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Option
Awards(1) ($) |
| |
Total
($) |
| |||||||||
Timothy C. Barabe
|
| | | $ | 60,250 | | | | | $ | 32,188 | | | | | $ | 92,438 | | |
Susan L. Kelley, M.D.
|
| | | | 54,000 | | | | | | 32,188 | | | | | | 86,188 | | |
Ronald M. Lindsay, Ph.D.
|
| | | | 74,000 | | | | | | 32,188 | | | | | | 106,188 | | |
Michael D. Loberg, Ph.D
|
| | | | 59,000 | | | | | | 32,188 | | | | | | 91,188 | | |
William G. Messenger, D. Min.
|
| | | | 65,250 | | | | | | 32,188 | | | | | | 97,438 | | |
Ran Nussbaum
|
| | | | 39,000 | | | | | | 32,188 | | | | | | 71,188 | | |
Patrick J. Zenner
|
| | | | 70,250 | | | | | | 40,235 | | | | | | 110,485 | | |
| Agenus Inc. | | | Eloxx Pharmaceuticals, Inc. | | | Mirati Therapeutics, Inc. | |
| Athersys, Inc. | | | Endocyte Inc. | | | Rigel Pharmaceuticals, Inc. | |
|
AVEO Pharmaceuticals, Inc.
|
| | Epizyme, Inc. | | |
Spring Bank Pharmaceuticals, Inc.
|
|
| Calithera Biosciences, Inc. | | | Geron Corporation | | | Sunesis Pharmaceutical, Inc. | |
| ChemoCentryx, Inc. | | | GTx, Inc. | | | Syndax Pharmaceuticals, Inc. | |
| CTI BioPharma Corp | | | Infinity Pharmaceuticals, Inc. | | | Verastem, Inc. | |
| Cytokinetics, Incorporated | | |
Karyopharm Therapeutics Inc.
|
| | Ziopharm Oncology, Inc. | |
Name and Principal Position
|
| |
2017
Annualized Base Salary ($) |
| |
2018
Annualized Base Salary ($) |
| |
%
Increase |
| |
Comment
|
| |||||||||
Paolo Pucci, CEO
|
| | | | 499,000 | | | | | | 506,000 | | | | | | 1.5 | | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. |
|
Peter S. Lawrence, COO
|
| | | | 448,000 | | | | | | 459,000 | | | | | | 2.5 | | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. |
|
Dr. Brian Schwartz, CMO
|
| | | | 446,000 | | | | | | 457,000 | | | | | | 2.5 | | | | Base salary negotiated in and adjusted per employment agreement and annual review. |
|
Robert J. Weiskopf, CFO
|
| | | | 317,000 | | | | | | 325,000 | | | | | | 2.5 | | | |
Base salary adjusted at annual review.
|
|
Name and Principal Position
|
| |
2018 Bonus Target
(% of Base Salary) |
| |
2018 Bonus Actual
(% of Base Salary) |
| |
Comment
|
|
Paolo Pucci, CEO
|
| |
60.0%
|
| |
60.0%
|
| | Target bonus set by terms of amended employment agreement. | |
Peter S. Lawrence, COO
|
| |
45.0%
|
| |
45.0%
|
| | Target bonus set by terms of amended employment agreement. | |
Dr. Brian Schwartz, CMO
|
| |
40.0%
|
| |
40.0%
|
| | Target bonus set by terms of employment agreement. | |
Robert J. Weiskopf, CFO
|
| |
40.0%
|
| |
40.0%
|
| | Bonus target set by Compensation Committee in accordance with annual process. | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($)(1) |
| |
Bonus
($) |
| |
Stock
Awards ($) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
($) |
|||||||||||||||||||||||
Paolo Pucci
Chief Executive Officer |
| | | | 2018 | | | | | | 506,302 | | | | | | — | | | | | | — | | | | | | 925,512 | | | | | | 303,971 | | | | | | 8,742 | | | | | | 1,744,527 |
| | | 2017 | | | | | | 498,718 | | | | | | — | | | | | | — | | | | | | 634,860 | | | | | | 248,568 | | | | | | 8,742 | | | | | | 1,390,888 | ||
| | | 2016 | | | | | | 489,345 | | | | | | — | | | | | | — | | | | | | 548,208 | | | | | | 255,438 | | | | | | 8,550 | | | | | | 1,301,541 | ||
Peter S. Lawrence
President, Chief Operating Officer, General Counsel and Secretary |
| | | | 2018 | | | | | | 458,591 | | | | | | — | | | | | | — | | | | | | 494,626 | | | | | | 206,579 | | | | | | 8,742 | | | | | | 1,168,538 |
| | | 2017 | | | | | | 447,140 | | | | | | — | | | | | | — | | | | | | 350,267 | | | | | | 167,279 | | | | | | 8,742 | | | | | | 973,428 | ||
| | | 2016 | | | | | | 430,286 | | | | | | — | | | | | | — | | | | | | 274,104 | | | | | | 168,597 | | | | | | 8,550 | | | | | | 881,536 | ||
Dr. Brian Schwartz
Chief Medical Officer and Senior Vice President |
| | | | 2018 | | | | | | 456,521 | | | | | | — | | | | | | — | | | | | | 409,554 | | | | | | 182,797 | | | | | | 8,742 | | | | | | 1,057,614 |
| | | 2017 | | | | | | 445,121 | | | | | | — | | | | | | — | | | | | | 275,106 | | | | | | 148,021 | | | | | | 8,742 | | | | | | 876,991 | ||
| | | 2016 | | | | | | 428,001 | | | | | | — | | | | | | — | | | | | | 237,557 | | | | | | 149,187 | | | | | | 8,550 | | | | | | 823,295 | ||
Robert J. Weiskopf
Chief Financial Officer and Treasurer |
| | | | 2018 | | | | | | 324,795 | | | | | | — | | | | | | — | | | | | | 92,336 | | | | | | 130,052 | | | | | | 8,742 | | | | | | 555,925 |
| | | 2017 | | | | | | 316,684 | | | | | | — | | | | | | — | | | | | | 183,369 | | | | | | 105,310 | | | | | | 8,742 | | | | | | 614,105 | ||
| | | 2016 | | | | | | 305,000 | | | | | | — | | | | | | — | | | | | | 137,052 | | | | | | 92,873 | | | | | | 8,550 | | | | | | 543,475 |
| | | | | | | | |
Estimated Future Payouts
Under Non-Equity Incentive Plan Awards(1) |
| |
All Other
Option Awards: Number of Securities Underlying Options (#) |
| |
Exercise or
base price of option awards ($/Sh) |
| |
Grant Date
Fair Value of Stock and Option Awards ($) |
| | | | ||||||||||||||||||||||||||||||
Name
|
| |
Grant Date
|
| |
Threshold
($) |
| |
Target
($) |
| |
Maximum
($) |
| | | | | | | | | | ||||||||||||||||||||||||||||||
Paolo Pucci
|
| | | | N/A | | | | | | — | | | | | | 316,130 | | | | | | 474,195 | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | | | | | 249,000 | | | | | | 1.75 | | | | | | 262,172 | | | | | | ||||||
| | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | | | | | 80,000 | | | | | | 2.48 | | | | | | 127,480 | | | | | | ||||||
| | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | | | | | 150,000 | | | | | | 5.48 | | | | | | 535,860 | | | | | | ||||||
Peter S. Lawrence
|
| | | | N/A | | | | | | — | | | | | | 214,842 | | | | | | 322,264 | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | | | | | 124,500 | | | | | | 1.75 | | | | | | 131,086 | | | | | | ||||||
| | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | | | | | 60,000 | | | | | | 2.48 | | | | | | 95,610 | | | | | | ||||||
| | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | | | | | 75,000 | | | | | | 5.48 | | | | | | 267,930 | | | | | | ||||||
Dr. Brian Schwartz
|
| | | | N/A | | | | | | — | | | | | | 190,109 | | | | | | 285,164 | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | | | | | 107,900 | | | | | | 1.75 | | | | | | 113,608 | | | | | | ||||||
| | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | | | | | 40,000 | | | | | | 2.48 | | | | | | 63,740 | | | | | | ||||||
| | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | | | | | 65,000 | | | | | | 5.48 | | | | | | 232,206 | | | | | | ||||||
Robert J. Weiskopf
|
| | | | N/A | | | | | | — | | | | | | 130,052 | | | | | | 195,078 | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | | | | | 62,250 | | | | | | 1.75 | | | | | | 65,543 | | | | | | ||||||
| | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | | | | | 7,500 | | | | | | 5.48 | | | | | | 26,793 | | | | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options (#)(1) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#)(1) Unexercisable |
| |
Option Exercise
Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Paolo Pucci
|
| | | | 225,000 | | | | | | | | | | | $ | 3.42 | | | | | | 1/21/2020 | | |
| | | | | 100,000 | | | | | | | | | | | | 4.14 | | | | | | 7/15/2020 | | |
| | | | | 300,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 315,000 | | | | | | | | | | | | 7.95 | | | | | | 2/1/2022 | | |
| | | | | 285,000 | | | | | | | | | | | | 2.51 | | | | | | 1/14/2023 | | |
| | | | | 305,000 | | | | | | | | | | | | 2.57 | | | | | | 1/22/2024 | | |
| | | | | 195,002 | | | | | | 97,500 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 240,000 | | | | | | 240,000 | | | | | | 1.79 | | | | | | 1/19/2026 | | |
| | | | | 75,000 | | | | | | 225,000 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | | | | | | | 600,000 | | | | | | 0.95 | | | | | | 4/4/2027 | | |
| | | | | | | | | | | 249,000 | | | | | | 1.75 | | | | | | 1/16/2028 | | |
| | | | | | | | | | | 80,000 | | | | | | 2.48 | | | | | | 5/8/2028 | | |
| | | | | | | | | | | 150,000 | | | | | | 5.48 | | | | | | 7/23/2028 | | |
Peter S. Lawrence
|
| | | | 130,000 | | | | | | | | | | | | 3.42 | | | | | | 1/21/2020 | | |
| | | | | 130,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 25,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 147,750 | | | | | | | | | | | | 7.95 | | | | | | 2/1/2022 | | |
| | | | | 123,500 | | | | | | | | | | | | 2.51 | | | | | | 1/14/2023 | | |
| | | | | 140,500 | | | | | | | | | | | | 2.57 | | | | | | 1/22/2024 | | |
| | | | | 126,750 | | | | | | 42,250 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 37,500 | | | | | | 12,500 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 120,000 | | | | | | 120,000 | | | | | | 1.79 | | | | | | 1/19/2026 | | |
| | | | | 37,500 | | | | | | 112,500 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | 8,750 | | | | | | 26,250 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | | | | | | | 300,000 | | | | | | 0.95 | | | | | | 4/4/2027 | | |
| | | | | | | | | | | 124,500 | | | | | | 1.75 | | | | | | 1/16/2028 | | |
| | | | | | | | | | | 60,000 | | | | | | 2.48 | | | | | | 5/8/2028 | | |
| | | | | | | | | | | 75,000 | | | | | | 5.48 | | | | | | 7/23/2028 | | |
Dr. Brian Schwartz
|
| | | | 90,000 | | | | | | | | | | | | 3.42 | | | | | | 1/21/2020 | | |
| | | | | 90,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 50,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 109,500 | | | | | | | | | | | | 7.95 | | | | | | 2/1/2022 | | |
| | | | | 85,500 | | | | | | | | | | | | 2.51 | | | | | | 1/14/2023 | | |
| | | | | 106,500 | | | | | | | | | | | | 2.57 | | | | | | 1/22/2024 | | |
| | | | | 87,750 | | | | | | 29,250 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 22,500 | | | | | | 7,500 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 104,000 | | | | | | 104,000 | | | | | | 1.79 | | | | | | 1/19/2026 | | |
| | | | | 32,500 | | | | | | 97,500 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | | | | | | | 260,000 | | | | | | 0.95 | | | | | | 4/4/2027 | | |
| | | | | | | | | | | 107,900 | | | | | | 1.75 | | | | | | 1/16/2028 | | |
| | | | | | | | | | | 40,000 | | | | | | 2.48 | | | | | | 5/8/2028 | | |
| | | | | | | | | | | 65,000 | | | | | | 5.48 | | | | | | 7/23/2028 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options (#)(1) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#)(1) Unexercisable |
| |
Option Exercise
Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Robert J. Weiskopf
|
| | | | 45,000 | | | | | | | | | | | | 3.42 | | | | | | 1/21/2020 | | |
| | | | | 45,000 | | | | | | | | | | | | 6.70 | | | | | | 1/24/2021 | | |
| | | | | 40,500 | | | | | | | | | | | | 7.95 | | | | | | 2/01/2022 | | |
| | | | | 42,750 | | | | | | | | | | | | 2.51 | | | | | | 1/14/2023 | | |
| | | | | 48,250 | | | | | | | | | | | | 2.57 | | | | | | 1/22/2024 | | |
| | | | | 43,875 | | | | | | 14,625 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 15,000 | | | | | | 5,000 | | | | | | 1.16 | | | | | | 1/20/2025 | | |
| | | | | 22,500 | | | | | | 7,500 | | | | | | 1.80 | | | | | | 6/01/2025 | | |
| | | | | 60,000 | | | | | | 60,000 | | | | | | 1.79 | | | | | | 1/19/2026 | | |
| | | | | 18,750 | | | | | | 56,250 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | 5,000 | | | | | | 15,000 | | | | | | 1.53 | | | | | | 1/17/2027 | | |
| | | | | | | | | | | 160,000 | | | | | | 0.95 | | | | | | 4/4/2027 | | |
| | | | | | | | | | | 62,250 | | | | | | 1.75 | | | | | | 1/16/2028 | | |
| | | | | | | | | | | 7,500 | | | | | | 5.48 | | | | | | 7/23/2028 | | |
Name
|
| |
Number of
Securities Acquired on Exercise |
| |
Value Realized
Upon Exercise ($) |
| ||||||
Paolo Pucci
|
| | | | 500,000 | | | | | | 2,861,519 | | |
Dr. Brian Schwartz
|
| | | | 200,000 | | | | | | 1,036,000 | | |
Name
|
| |
Cash
Payment(1) ($) |
| |
Equity
Acceleration ($) |
| |
Benefits and
Perquisites(2) ($) |
| |
Total
($) |
| ||||||||||||
Paolo Pucci
|
| | | $ | 1,555,413 | | | | | $ | 2,040,355 | | | | | $ | 51,261 | | | | | $ | 3,647,029 | | |
Peter S. Lawrence
|
| | | | 627,003 | | | | | | 1,068,188 | | | | | | 25,630 | | | | | | 1,720,821 | | |
Dr. Brian Schwartz
|
| | | | 605,597 | | | | | | 876,846 | | | | | | 25,630 | | | | | | 1,508,073 | | |
| | |
2018
|
| |
2017
|
| ||||||
Audit Fees
|
| | | $ | 562,000 | | | | | $ | 544,000 | | |
Audit-Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total
|
| | | $ | 562,000 | | | | | $ | 544,000 | | |
|
Name
|
| |
Common
Stock Owned |
| |
Warrants to
Purchase Common Stock |
| |
Options to
Purchase Common Stock |
| |
Total Shares
Beneficially Owned |
| |
Percent
of Class |
| |||||||||||||||
First Eagle Investment Management, LLC (1)
1345 Avenue of the Americas, New York, NY 10105 |
| | | | 16,081,128 | | | | | | | | | | | | | | | | | | 16,081,128 | | | | | | 14.7% | | |
Nantahala Capital Management, LLC(2)
19 Old Kings Highway S, Suite 200, Darien, CT 06820 |
| | | | 12,101,879 | | | | | | 535,242 | | | | | | | | | | | | 12,637,121 | | | | | | 11.5% | | |
BlackRock, Inc.(3)
55 East 52nd Street, New York, NY 10055 |
| | | | 8,618,012 | | | | | | | | | | | | | | | | | | 8,618,012 | | | | | | 7.9% | | |
BVF Inc.(4)
44 Montgomery St., 40th Floor San Francisco, California 94104 |
| | | | 6,230,418 | | | | | | 2,439,932 | | | | | | | | | | | | 8,670,350 | | | | | | 7.8% | | |
Pontifax Group(5)
14 Shenkar Street Herzliya Pituach 46140, Israel |
| | | | 6,798,429 | | | | | | 1,784,000 | | | | | | 30,000 | | | | | | 8,612,429 | | | | | | 7.8% | | |
Vanguard Group(6)
100 Vanguard Blvd, Malvern, PA 19355 |
| | | | 5,465,858 | | | | | | | | | | | | | | | | | | 5,465,858 | | | | | | 5.0% | | |
Directors and Executive Officers(1)
|
| |
Common
Stock Owned |
| |
Options to
Purchase Common Stock |
| |
Warrants to
Purchase Common Stock |
| |
Total Shares
Beneficially Owned |
| |
Percent
of Class |
| |||||||||||||||
Timothy C. Barabe(2)
|
| | | | 136,897 | | | | | | 160,000 | | | | | | | | | | | | 296,897 | | | | | | * | | |
Susan L. Kelley
|
| | | | 50,000 | | | | | | 165,000 | | | | | | | | | | | | 215,000 | | | | | | * | | |
Ronald M. Lindsay
|
| | | | 50,800 | | | | | | 160,000 | | | | | | | | | | | | 210,800 | | | | | | * | | |
Michael D. Loberg
|
| | | | 162,514 | | | | | | 160,000 | | | | | | | | | | | | 322,514 | | | | | | * | | |
William G. Messenger
|
| | | | 10,000 | | | | | | 160,000 | | | | | | | | | | | | 170,000 | | | | | | * | | |
Ran Nussbaum(3)
|
| | | | 6,798,429 | | | | | | 30,000 | | | | | | 1,784,000 | | | | | | 8,612,429 | | | | | | 7.8% | | |
Patrick J. Zenner
|
| | | | 82,216 | | | | | | 240,000 | | | | | | | | | | | | 322,216 | | | | | | * | | |
Peter S. Lawrence
|
| | | | 77,743 | | | | | | 1,234,375 | | | | | | | | | | | | 1,312,118 | | | | | | 1.2% | | |
Paolo Pucci
|
| | | | 699,378 | | | | | | 2,364,752 | | | | | | | | | | | | 3,064,130 | | | | | | 2.7% | | |
Brian Schwartz
|
| | | | 115,317 | | | | | | 936,475 | | | | | | | | | | | | 1,051,792 | | | | | | 1.0% | | |
Robert J. Weiskopf
|
| | | | 30,407 | | | | | | 475,562 | | | | | | | | | | | | 505,969 | | | | | | * | | |
Directors and executive officers as a group (11 persons)
|
| | | | 8,213,701 | | | | | | 6,086,164 | | | | | | 1,784,000 | | | | | | 16,083,865 | | | | | | 13.8% | | |
|